AFMD - Affimed N.V.

-

$undefined

N/A

(N/A)

Affimed N.V. NASDAQ:AFMD Affimed is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company's proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager (ICE®) molecules, which use patients' immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE®. Headquartered in Heidelberg, Germany, with offices in New York, New York, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients' lives.

Location: | Website: www.affimed.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

26.95M

Cash

34.45M

Avg Qtr Burn

-21.01M

Short % of Float

4.68%

Insider Ownership

6.01%

Institutional Own.

34.83%

Qtr Updated

06/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
AFM24 (tumor target EGFR) w/ SNK01 & atezolizumab Details
Solid tumor/s, Cancer, Non-small cell lung carcinoma

Phase 2

Data readout

AFM13 (Acimtamig) + AB-101 Details
Lymphoma, Cancer, Peripheral T-cell Lymphomas, Hodgkin Lymphoma

Phase 2

Data readout

AFM13 (Acimtamig)+ cbNK cells Details
Cancer, Non-Hodgkin lymphoma

Phase 2

Update

AFM13 (Acimtamig) Details
Peripheral T cell cancer , Cancer

Phase 2

Initiation

AFM28 Details
Cancer, Acute myeloid leukemia, Blood cancer, Leukemia

Phase 1

Data readout

AFM24 (tumor target EGFR) Monotherapy Details
Solid tumor/s, Cancer, Non-small cell lung carcinoma, Colorectal cancer

Failed

Discontinued

RO7297089 (formerly AFM26) Details
Multiple myeloma, Cancer

Failed

Discontinued